Conatus Shares Plummet After Emricasan Study Misses Primary Endpoint
21 Março 2019 - 06:49PM
Dow Jones News
By Colin Kellaher
Shares of Conatus Pharmaceuticals Inc. (CNAT) lost more than
half of their value in after-hours trading Thursday after the
company said a phase 2b trial of emricasan missed its primary
endpoint in patients with biopsy-confirmed nonalcoholic
steatohepatitis, or NASH, and liver fibrosis.
The San Diego biotechnology company said that while the drug
didn't have the desired effect in earlier-stage NASH fibrosis
patients, it warrants continued evaluation in more advanced-stage
NASH cirrhosis patients.
Conatus said it expects to receive more data over the coming
months and will review the results with Novartis AG (NVS) "to
determine the most appropriate path forward."
Conatus in late 2016 inked an exclusive collaboration and
license agreement with Novartis for the development and
commercialization of emricasan. The deal included a $50 million
upfront payment from Novartis.
Shares of Conatus, which closed Thursday at $2.91, plunged 52%
to $1.39 in after-hours trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 21, 2019 17:34 ET (21:34 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Conatus Pharmaceuticals (NASDAQ:CNAT)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024
Notícias em tempo-real sobre Conatus Pharmaceuticals Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Conatus Pharmaceuticals Inc.